Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma
Steven A. Rosenberg; James C. Yang; Douglas J. Schwartzentruber; Patrick Hwu; Suzanne L. Topalian; Richard M. Sherry; Nicholas P. Restifo; John R. Wunderlich; Claudia A. Seipp; et al. (Profiled Author: Patrick Hwu)
Clinical Cancer Research. 2003;9(8):2973-2980.Abstract
Purpose: The purpose of this study was to evaluate the immunological responses and therapeutic effectiveness of immunization with fowlpox vaccines encoding the gp100 melanoma antigen in patients with metastatic melanoma. Experimental Design: In three consecutive clinical trials, patients were immunized with recombinant fowlpox viruses encoding three different forms of the melanoma/melanocyte-associated antigen gp100: (a) the native, full-length gp100 molecule; (b) the gp100 molecule with two amino acids modified to increase binding to HLA-A*0201 molecules; and (c) a "minigene" construct encoding a single, modified epitope gp100:209-217(210M) targeted to the endoplasmic reticulum. The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-γ. Results: Reactivity against gp100 was not seen in any patient before receiving fowlpox immunization. Whereas just one of seven patients developed reactivity after receiving fowlpox encoding native gp100, 10 of 14 patients who received fowlpox encoding the anchor modified full-length gp100 exhibited reactivity against the native gp100 molecule, and 12 of 16 patients were successfully immunized after inoculation with the modified minigene construct (p2 = 0.02). There was no difference in the latter group between those randomized to vaccination by i.v. or i.m. routes. There was one partial cancer regression in the group of 46 patients receiving virus in the absence of interleukin (IL)-2. Once patients showed evidence of progressive disease, they were eligible for "cross-over" treatment to IL-2 alone or with the fowlpox virus. None of the 13 patients receiving the full-length or modified full-length forms of gp100 responded when receiving IL-2, whereas 6 of 12 patients who received the fowlpox containing the minigene construct and then received IL-2 showed objective cancer regressions, including three patients with complete regression. Conclusions: These data underscore the importance of modifying anchor residues of nonmutated self-antigen peptides to generate cellular immune responses after immunization and support the further investigation of recombinant fowlpox viruses encoding modified epitopes administered in combination with IL-2.
PMID: 12912944 PMCID: PMC2259234
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Giao Q. Phan; Christopher E. Touloukian; James C. Yang; Nicholas P. Restifo; Richard M. Sherry; Patrick Hwu; Suzanne L. Topalian; Douglas J. Schwartzentruber; Claudia A. Seipp; et al.Journal of Immunotherapy. 2003;26(4):349-356.
Gerald P. Linette; Dongsheng Zhang; F. Stephen Hodi; Eric P. Jonasch; Simonne Longerich; Christopher P. Stowell; Iain J. Webb; Heather Daley; Robert J. Soiffer; Amy M. Cheung; et al.Clinical Cancer Research. 2005;11(21):7692-7699.
Maria P. Bettinotti; Christina J. Kim; Kang-Hun Lee; Matthew Roden; Janice N. Cormier; Monica Panelli; Kenneth K. Parker; Francesco M. MarincolaJournal of Immunology. 1998;161(2):877-889.
Appears in this Document